Top Five Pharma saves $5,000 per document

The challenge

The Oncology Development Group faced a document collaboration process that was slow, frustrating and not fit for purpose. Teams of up to 50 reviewers, spanning multiple disciplines and external academic researchers, were collaborating by email via Office 365, resulting in version confusion, lost comments and a broken audit trail.

• Exceptionally large, complex documents
• External collaboration with CROs & academics
• Multiple file formats to manage
• No redaction capabilities
• No audit trail, change tracking or version control
• No review management capabilities

These issues slowed productivity and efficiency in an already lengthy process - one where the stakes, in terms of regulatory compliance and patient outcomes, are extremely high.

The team set out to find a solution that would save time, effort and money - without compromising on the rigorous standards required by regulators such as the FDA. The software had to be agile, affordable and quick to deploy.
 

The solution

Ideagen’s cloud-based platform gave the team a smart and secure way to streamline the entire document review lifecycle - from real-time co-authoring and concurrent review, to full redaction and an end-to-end audit trail.

During the COVID-19 pandemic - a period that magnified many of the processes that handcuffed teams when they were trying to get work done at an accelerated pace -  Please Review enabled the company to maintain momentum and collaborate effectively under remote working conditions, keeping pace with other vaccine developers.
 

The results

As a company producing tens of thousands of documents a year, they conducted a rigorous cost analysis - comparing manual task completion times with Please Review. The results exceeded all expectations.

"This was beyond what senior stakeholders could have imagined for a tool like this. Ideagen Please Review has provided agility and flexibility that has allowed for growth in the organisation.”

Word spread quickly. Once other divisions saw the results, they joined the beta testing group and became advocates. Multiple voices across all levels, teams and stakeholders clamoured for the tool once they saw what it could do.

As the Head of Oncology noted: “Innovation is difficult in this industry, so this approach was absolutely necessary.”

Teams now using Ideagen Please Review:

• Global Medical Writing
• Infectious Diseases
• Vaccines    
• Immunology
• Oncology    
• Centralised Development Group    
• Speciality Development    
• Research & Development (R&D)
   

The partnership

A dedicated team at Ideagen made the transition to Please Review an easy move for all the groups involved.